Gilead Sciences (NASDAQ:GILD) Price Target Cut to $76.00 by Analysts at Royal Bank of Canada

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price decreased by equities researchers at Royal Bank of Canada from $78.00 to $76.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would suggest a potential […]

Related Keywords

Canada ,United States ,Leerink Partnrs ,Johanna Mercier ,Andrewd Dickinson ,Complera Eviplera ,Wells Fargo Company ,Deutsche Bank Aktiengesellschaft ,Norges Bank ,Analyst Recommendations For Gilead Sciences ,Securities Exchange Commission ,Barclays ,Arrowstreet Capital Limited Partnership ,News Ratings For Gilead Sciences Daily ,Moneta Group Investment Advisors ,Renaissance Technologies ,Gilead Sciences Stock Performance ,Gilead Sciences Inc ,Royal Bank ,Gilead Sciences Company Profile ,Insider Transactions At Gilead Sciences ,Gilead Sciences ,Get Free Report ,Bank Aktiengesellschaft ,Wells Fargo ,Exchange Commission ,Capital Limited Partnership ,Group Investment Advisors ,Capital World Investors ,World Investors ,Gilead Sciences Daily ,Nasdaq Gild ,Gild ,Medical ,37555810 ,Lower Price Target ,Royal Bank Of Canada ,